Sinopharm to acquire Aurobindo's Chinese antibiotics subsidiary
This article was originally published in Scrip
Executive Summary
Aurobindo Pharma is divesting its loss-making Chinese arm to China National Pharmaceutical Group Corp (Sinopharm), in a move expected to boost Aurobindo's overall cash flow and operating margins as the company transitions away from active pharmaceutical ingredients to the formulations business.